On April 22, 2024 Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, reported the acceptance of two abstracts at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 2024 Annual Meeting being held May 7-11, 2024, in Baltimore, MD (Press release, Carisma Therapeutics, APR 22, 2024, View Source [SID1234642214]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to present new preclinical data highlighting the potential of our engineered macrophage cell therapies for the treatment of liver and lung fibrosis, both of which represent significant unmet medical needs with limited available therapies for patients," said Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer of Carisma. "We look forward to presenting these data and are excited to expand our macrophage engineering platform beyond oncology."
Poster Presentation Details:
Title: Genetically Engineered Macrophage Cell Therapy Reverses Liver and Lung Fibrosis in Preclinical Models
Abstract #: 852
Session: Other Cellular and Regenerative Therapies
Date & Time: Wednesday, May 8, 2024; 12:00 PM ET
Location: Exhibit Hall
Title: Redirected Soluble Modulators (RSM) – A Novel Engineering Strategy to Enhance Immune Receptor Signaling
Abstract #: 812
Session: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies
Date & Time: Wednesday, May 8, 2024; 12:00 PM ET
Location: Exhibit Hall
The posters presented at ASGCT (Free ASGCT Whitepaper) 2024 will be available online in the "Publications" section of Carisma’s website at View Source following the start of the respective poster sessions.